WO1987001460A1 - Test device for determination of blood in faeces - Google Patents

Test device for determination of blood in faeces Download PDF

Info

Publication number
WO1987001460A1
WO1987001460A1 PCT/NO1986/000060 NO8600060W WO8701460A1 WO 1987001460 A1 WO1987001460 A1 WO 1987001460A1 NO 8600060 W NO8600060 W NO 8600060W WO 8701460 A1 WO8701460 A1 WO 8701460A1
Authority
WO
WIPO (PCT)
Prior art keywords
faeces
paper
blood
chromogen
peroxide
Prior art date
Application number
PCT/NO1986/000060
Other languages
French (fr)
Inventor
Terje Silsand
Original Assignee
Terje Silsand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terje Silsand filed Critical Terje Silsand
Publication of WO1987001460A1 publication Critical patent/WO1987001460A1/en
Priority to DK180587A priority Critical patent/DK180587A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G01N33/521Single-layer analytical elements
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721Haemoglobin
    • G01N33/725Haemoglobin using peroxidative activity

Definitions

  • the invention concerns a test device for determin ⁇ ation of blood in faeces.
  • blood act as a catalyst in a reaction in which a colour ⁇ less chromogen is transformed to a strongly coloured com- pound when hydrogenperoxide (H Tail0_) is added to the systems, or is generated in the systems.
  • H Tail0_ hydrogenperoxide
  • a development of colour is interprated as positive; that blood can be present in faeces.
  • heme will dissociate from hemoglobin in an acid solution and act as a pseudoperoxidase.
  • Faeces is applied on a piece of paper.
  • the paper may be impregnated with a chromogen (guaiacol is mostly used) or not impreg- nated.
  • a chromogen guaiacol is mostly used
  • H O diss ⁇ olved in an alcohol-containing solvent
  • a solution containing a chromogen e.g. 3 , 3' , 5 , 5' -tetramethylbenzidine (TMB) dissolved in a strongly acid alcohol-containing solvent
  • TMB a chromogen
  • Common for the systems are that in the presence of blood a colour development occurs on and at the edge of the faeces.
  • the hitherto described systems are constructed n such a way that the paper, with or without chromogen at the same time is carrier for the faeces.
  • a carrier is here defined as a place where the faeces is stored until assay is performed.
  • the systems are primarily constructed for the purpose that the patient himself applies faeces at home for later on to bring the paper to the physician or laboratory. This require that no reaction must take place between blood in the faeces and components on the paper. At hospitals the assay is mostly performed shortly after applying the sample on the paper.
  • the systems described hitherto where the paper is impregnated with chromogen (guaiacol) suffer from some disadvantages.
  • One of these systems is produced by Lab- systems, Helsinki, Finland, and is sold under the trade-
  • Hemoccult Another of the systems with chromoge ⁇ -impregnated paper is "Hemoccult" (U.S. Patent No 3,996,006).
  • One disadvan- tage in this system is that faeces cannot be stored for more than 12 days before assay must be performed.
  • Chromogen-impregnated paper may give false positive react ⁇ ion when peroxidases from unboiled vegetables are present in faeces. Such peroxidases may, in sufficiently high concentrations, oxidase the chromogen to a coloured com ⁇ pound in the absence of peroxide. It has been shown ( own unpublished results) that guaiacol-based systems gave positive reaction in the presence of horse radish perox- idase without adding peroxide.
  • the carrier as defined here, is peroxide-impregnated and not chromogen-impregnated one avoids the disadvantages described for the chromogen- based systems.
  • the new system keeps chromogen separated from peroxide (and applied faeces) until assay is performed.
  • the system allows performance of assay immediately after applying faeces, e.g. in a hospital.
  • the system also allows the patient to apply the sample in his home for later on to bring the paper to physician or laboratory for assay. Own experiments show that applied samples can be stored for at least 10 weeks at room temperature before assay is performed. It will be understood that physician or laboratory shall perform the assay. Law regulations in very many co ⁇ tries makes it ineco ⁇ omical for the patient to perform the assay in his home .
  • the new system thus differs from European Patent Application nr. 93595 by keeping peroxide and chromogen separate, and that the peroxide-impregnated paper first serves as carrier (storage place) for faeces, and later as analytical part of the system when chromogen is applied.
  • European Patent Application 93595 is also based on a reaction in an aqueous system, while the new system employs mainly ethanol and acetic acid and very little ater. It can here be mentioned that by increasing the amount of water in test systems for determination of blood in faeces the risk increases for obtaining false positive reactions due to the presence of peroxidases from vegetables in faeces. For .
  • acetic acid should not exceed 0.5 N when the concentration of sodiumperbora e is 100 g/1.
  • the paper impregnated with sufficient amounts of sodiumperborate shows long stability as part of the reagents ' used for determination of blood in faeces; It can
  • the test device is composed of two reagents, here ⁇ after designated Reagent A and Reagent B.
  • Reagent A is an absorbing paper impregnated with a solid peroxide-contain ⁇ ing compound, here sodiumperborate. The paper serves both as a carrier for the system's peroxide and as an applicat ⁇ ion paper (storage place) for the faeces sample.
  • Reagent B contains 3 , 3 ' , 5 , 5 ' -tetramethy lbenzidine (TMB) dissolved in ethy la lcoho1 , acetic acid and water. Histidine is added to the solution to stabilize TMB. (R.M. Jaffe and W . Zierdt. J Lab Clin Med. (1979) 93, 879-886).
  • Reagent B is added to the faeces sample applied on Reagent "A .
  • Reagent "A In the presence of blood blue-bluishgreen colour devel- opes on and at the edge of the faeces sample.
  • the reaction between blood, chromogen and peroxide is very fast, e.g. a sample containing approximately 1 ml blood (with hemoglobin concentration approximately 15 g/100 ml) pr. 100 g faeces will give a distinct colour within 5-10 seconds.
  • the test device is described in its simplest form, and any variation in packaging technique, especially for covering the faeces sample, will not change the principle of the test dev ice .
  • Reagent B has the following prefered composition: 3 , 3' , 5, 5' -tetramethy lbenzidine 2 g/1 solution

Abstract

Faeces is applied on an absorbing paper impregnated with a solid peroxide-giving compound, here sodiumperborate. To the faeces sample is added a chromogen, 3,3',5,5'-tetramethylbenzidine, dissolved in acetic acid, ethanol and water and stabilized by adding histidine. When blood is present in the faeces sample blue-bluishgreen colour developes on and at the edge of the faeces sample. Coulor development can occur within 5-10 seconds when the sample contains 1 ml blood pr. 100 g faeces. The analytical system thus employs only one single reagent when the assay is performed because the system's peroxide-giving part is impregnated on the same carrier on to which the faeces is applied.

Description

TEST DEVICE FOR DETERMINATION OF BLOOD IN FAECES.
The invention concerns a test device for determin¬ ation of blood in faeces. Common for all systems are that blood act as a catalyst in a reaction in which a colour¬ less chromogen is transformed to a strongly coloured com- pound when hydrogenperoxide (H„0_) is added to the systems, or is generated in the systems. A development of colour is interprated as positive; that blood can be present in faeces. Common for all systems is that heme will dissociate from hemoglobin in an acid solution and act as a pseudoperoxidase.
The systems currently in use are, with few exceptions, constructed in the following way: Faeces is applied on a piece of paper. The paper may be impregnated with a chromogen (guaiacol is mostly used) or not impreg- nated. In the systems with impregnated paper H O , diss¬ olved in an alcohol-containing solvent, is applied to the paper. In the systems where the paper is not impregnated with a chromogen a solution containing a chromogen (e.g. 3 , 3' , 5 , 5' -tetramethylbenzidine (TMB) dissolved in a strongly acid alcohol-containing solvent) is added to the paper followed by adding a solution of H„0_. Common for the systems are that in the presence of blood a colour development occurs on and at the edge of the faeces.
The hitherto described systems are constructed n such a way that the paper, with or without chromogen at the same time is carrier for the faeces. A carrier is here defined as a place where the faeces is stored until assay is performed. The systems are primarily constructed for the purpose that the patient himself applies faeces at home for later on to bring the paper to the physician or laboratory. This require that no reaction must take place between blood in the faeces and components on the paper. At hospitals the assay is mostly performed shortly after applying the sample on the paper. The systems described hitherto where the paper is impregnated with chromogen (guaiacol) suffer from some disadvantages. One of these systems is produced by Lab- systems, Helsinki, Finland, and is sold under the trade-
to* mark "Fecatwin Sensitive". The manufacturer recommends to store the faeces on the paper for at least 2 hours before performing the assay, and claims that 72 hours storage ensures best result. The rate of positive findings is far higher when the samples are stored for 72 hours, which is confirmed by Dybdahl. (Dybdahl J.H., Studies on Occult Faecal Blood Loss, Thesis, Det medisinske fakultet, Uni- versitetet i Oslo, 1983). It is an obvious disadvantage that a test's sensitivity is dependent on the storage time of the sample, and the disadvantage is very serious when the assay may give false negative result when assay is performed shortly after applying the sample. Another of the systems with chromogeπ-impregnated paper is "Hemoccult" (U.S. Patent No 3,996,006). One disadvan- tage in this system is that faeces cannot be stored for more than 12 days before assay must be performed. Chromogen-impregnated paper may give false positive react¬ ion when peroxidases from unboiled vegetables are present in faeces. Such peroxidases may, in sufficiently high concentrations, oxidase the chromogen to a coloured com¬ pound in the absence of peroxide. It has been shown ( own unpublished results) that guaiacol-based systems gave positive reaction in the presence of horse radish perox- idase without adding peroxide. Such unwanted reactions cannot occur when faeces is stored on paper impregnated with peroxide in the absence of chromogen. Test devices where carrier is chromogen-impregnated may also autooxidase, and the production process makes it simpler to impregnate with peroxide than chromogen. The guaiacol-based systems cannot be stored at low temperature, + 4 C or lower. Distribution may therefore be a problem in the cold season.
By making a system where the carrier, as defined here, is peroxide-impregnated and not chromogen-impregnated one avoids the disadvantages described for the chromogen- based systems. The new system keeps chromogen separated from peroxide (and applied faeces) until assay is performed. The system allows performance of assay immediately after applying faeces, e.g. in a hospital. The system also allows the patient to apply the sample in his home for later on to bring the paper to physician or laboratory for assay. Own experiments show that applied samples can be stored for at least 10 weeks at room temperature before assay is performed. It will be understood that physician or laboratory shall perform the assay. Law regulations in very many coπtries makes it inecoπomical for the patient to perform the assay in his home .
Use of solid peroxide compound is known (European Patent Application nr. 93595), and then combined with a chromogen (guaiacol) to form a single reagent package. The described reagent package seems to be constructed for depo- siting it in a toilet bowl containing faeces. Hemoglobin dissolved in the water will catalyze the reaction between chromogen and peroxide. Faeces cannot be stored on the reagent package for subsequent assay as described for the systems with chromogen-impregnated paper, and as described for the new system. The reason is that water in faeces may dissolve chromogen and peroxide causing the catalytical reaction to start.
The new system thus differs from European Patent Application nr. 93595 by keeping peroxide and chromogen separate, and that the peroxide-impregnated paper first serves as carrier (storage place) for faeces, and later as analytical part of the system when chromogen is applied. European Patent Application 93595 is also based on a reaction in an aqueous system, while the new system employs mainly ethanol and acetic acid and very little ater. It can here be mentioned that by increasing the amount of water in test systems for determination of blood in faeces the risk increases for obtaining false positive reactions due to the presence of peroxidases from vegetables in faeces. For . practica 1 purpose the new system use absorbing paper impregnated with a solid peroxide-containing compound, here sodiumperborate . In principle this is simple, but not without problems. Experiments with differnt types of paper show that sodiumperborate is very unstable when impregnated on certain types of paper in the meaning that after a short period of time the reaction between blood and chromogen is not obtained. For those types of paper which show bad stab-' ility for sodiumperborate the problem can be solved by dissolving sodiumperborate in an aqueous solution containing organic acid, e.g. acetic acid, or a mixture of acetic acid and citric acid. By using organic acid one obtains that
10 higher concentrations of sodiumperborate can be prepared compared to an aqueous solution not .containing organic acid. The impregnation of the paper can be done in one operation using a concentrated solution of sodiumperborate containing organic acid instead of repeated impregna ions in less
15'* concentrated solutions, thus simplifying the impregnation. To ensure optimal stability of the paper impregnated with sodiumperborate the concentration of sodiumpe borate and acid must be balanced, avoiding too high concentration of acid. The ratio can be exemplified: The concentration of
20 acetic acid should not exceed 0.5 N when the concentration of sodiumperbora e is 100 g/1.
The paper impregnated with sufficient amounts of sodiumperborate shows long stability as part of the reagents' used for determination of blood in faeces; It can
25. be stored at least 12 months when refrigerated. To obtain such effect it is sufficient to impregnate the paper once in a 100 g/1 sodiumperborate solution containing organic acid. An alternative way to impregnate the paper is to use less concentrated solutions of sodiumperborate without
30 organic acid, with repeated impregnations and drying. This alternative can be used using paper types showing sufficient stability of sodiumperborate in the absence of organic acid.
35r; Description of the test device.
The test device is composed of two reagents, here¬ after designated Reagent A and Reagent B. Reagent A is an absorbing paper impregnated with a solid peroxide-contain¬ ing compound, here sodiumperborate. The paper serves both as a carrier for the system's peroxide and as an applicat¬ ion paper (storage place) for the faeces sample. Reagent B contains 3 , 3 ' , 5 , 5 ' -tetramethy lbenzidine (TMB) dissolved in ethy la lcoho1 , acetic acid and water. Histidine is added to the solution to stabilize TMB. (R.M. Jaffe and W . Zierdt. J Lab Clin Med. (1979) 93, 879-886).
Reagent B is added to the faeces sample applied on Reagent "A . In the presence of blood blue-bluishgreen colour devel- opes on and at the edge of the faeces sample. The reaction between blood, chromogen and peroxide is very fast, e.g. a sample containing approximately 1 ml blood (with hemoglobin concentration approximately 15 g/100 ml) pr. 100 g faeces will give a distinct colour within 5-10 seconds. The test device is described in its simplest form, and any variation in packaging technique, especially for covering the faeces sample, will not change the principle of the test dev ice .
Table 1. Composition of the test device
Reagent A has the following prefered composition: A piece of filter paper is dipped in a solution of sodiumperborate, - 100 g/1, containing acetic acid up to 0.5 N. A mixture of acetic acid and citric acid can be used instead of acetic acid alone: Normality acetic acid :Normality citric acid= 3:1, with maximum acid concentration 0.5 N. Alternatively, the paper can be impregnated in less concentrated sαdium- perborate solutions without organic acids, with repeated impregnations and drying.
Reagent B has the following prefered composition: 3 , 3' , 5, 5' -tetramethy lbenzidine 2 g/1 solution
Ethylalcohol 500 ml/1 solution - Acetic acid 350 ml/l solution
Water 150 ml/1 solution
Histidine 4 g/1 solution

Claims

P A T E N T C L A I M
1. Test device for determination of blood in faeces composed of two separated reagents; a filter paper 5 impregnated with solid peroxide, her by dipping the paper in a solution of sodiumperborate with concentration equivalent to 60-120 g/1, and a liquid reagent containing a chromogen ( 3 , 3 ' , , 5 ' -tetramethylbenzidine (1-3 g/1) dissolved in ethano 1 : acetic acid:water= 5:3.5:1.5, containing
10 histidine (4g/l), c h a r a c t e r i z e d b y that peroxide and chromogen are separated, and that the faeces sample is applied to the peroxide-impregnated filter paper and can be stored there until the assay is performed by adding the chromogen to the filter paper containing faeces
15 and peroxide whereby colour developes in the presence of blood .
20
2.5
30
35
PCT/NO1986/000060 1985-08-30 1986-08-26 Test device for determination of blood in faeces WO1987001460A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK180587A DK180587A (en) 1985-08-30 1987-04-09 TEST EQUIPMENT FOR DETERMINING BLOOD IN FAECES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO853413A NO157437C (en) 1985-08-30 1985-08-30 TESTING DEVICE FOR DETERMINING BLOOD IN FAECES.
NO853413 1985-08-30

Publications (1)

Publication Number Publication Date
WO1987001460A1 true WO1987001460A1 (en) 1987-03-12

Family

ID=19888455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NO1986/000060 WO1987001460A1 (en) 1985-08-30 1986-08-26 Test device for determination of blood in faeces

Country Status (5)

Country Link
EP (1) EP0235241A1 (en)
AU (1) AU6286186A (en)
DK (1) DK180587A (en)
NO (1) NO157437C (en)
WO (1) WO1987001460A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673654A (en) * 1985-10-31 1987-06-16 Warner-Lambert Company Composition for determining peroxidase-like activity of hemoglobin

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3092463A (en) * 1959-11-02 1963-06-04 Miles Lab Stable blood detecting composition
GB981955A (en) * 1961-05-04 1965-02-03 Miles Lab Improvements in or relating to diagnostic compositions
US3996006A (en) * 1974-08-16 1976-12-07 Smithkline Corporation Specimen test slide
SE408489B (en) * 1974-10-16 1979-06-11 Lachema Np DIAGNOSTIC TEST STRIP FOR DETERMINATION OF BLOOD AND HEMOGLOBIN IN BIOLOGICAL MATERIALS
EP0030388A2 (en) * 1979-12-10 1981-06-17 Baylor College of Medicine Methods for detecting and quantifying occult blood in a human specimen
US4333734A (en) * 1980-01-18 1982-06-08 Sloan-Kettering Institute For Cancer Research Diagnostic device for fecal occult blood and method of use
EP0093595A1 (en) * 1982-04-30 1983-11-09 Hematec Corporation Home diagnostic aid and method for determining the presence of occult blood
US4511533A (en) * 1982-10-07 1985-04-16 Helena Laboratories Corporation Test kit for performing a medical test
US4582685A (en) * 1982-10-07 1986-04-15 Helena Laboratories Corporation Test kit for performing a medical test

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3092463A (en) * 1959-11-02 1963-06-04 Miles Lab Stable blood detecting composition
GB981955A (en) * 1961-05-04 1965-02-03 Miles Lab Improvements in or relating to diagnostic compositions
US3252762A (en) * 1961-05-04 1966-05-24 Miles Lab Stabilized occult blood diagnostic
US3996006A (en) * 1974-08-16 1976-12-07 Smithkline Corporation Specimen test slide
SE408489B (en) * 1974-10-16 1979-06-11 Lachema Np DIAGNOSTIC TEST STRIP FOR DETERMINATION OF BLOOD AND HEMOGLOBIN IN BIOLOGICAL MATERIALS
EP0030388A2 (en) * 1979-12-10 1981-06-17 Baylor College of Medicine Methods for detecting and quantifying occult blood in a human specimen
US4333734A (en) * 1980-01-18 1982-06-08 Sloan-Kettering Institute For Cancer Research Diagnostic device for fecal occult blood and method of use
EP0093595A1 (en) * 1982-04-30 1983-11-09 Hematec Corporation Home diagnostic aid and method for determining the presence of occult blood
US4511533A (en) * 1982-10-07 1985-04-16 Helena Laboratories Corporation Test kit for performing a medical test
US4582685A (en) * 1982-10-07 1986-04-15 Helena Laboratories Corporation Test kit for performing a medical test

Also Published As

Publication number Publication date
NO157437B (en) 1987-12-07
DK180587D0 (en) 1987-04-09
NO853413L (en) 1987-03-02
DK180587A (en) 1987-04-09
AU6286186A (en) 1987-03-24
EP0235241A1 (en) 1987-09-09
NO157437C (en) 1988-03-16

Similar Documents

Publication Publication Date Title
EP0041188B1 (en) Interference-resistant composition, device, method of preparing it and method for determining a peroxidatively active substance in a test sample
Lundquist The determination of ethyl alcohol in blood and tissues
FI77894B (en) FOERFARANDE FOER FRAMSTAELLNING AV ETT ANALYTISKT ELEMENT FOER BESTAEMNING AV GLUKOS I HOEG KONSENTRATION.
US6998248B2 (en) Reagent test strip for analyte determination having a hemolyzing agent
EP0123115B1 (en) Ascorbate interference-resistant composition, device and method for the determination of peroxidatively active substances
CA2295617C (en) Method, composition and device for the determination of free halogens in aqueous fluids
EP0030684A1 (en) Test composition for peroxidatively active substances, test device containing the composition, process for preparing same and method for the determination of peroxidatively active substances
EP0030682B1 (en) Test composition for peroxidatively active substances, test device containing the composition, process for preparing same and method for the determination of peroxidatively active substances
EP0555045A1 (en) Improved oxidative coupling dye for spectrophotometric quantitative analysis of analytes
US4673654A (en) Composition for determining peroxidase-like activity of hemoglobin
HU224897B1 (en) Visually-readable reagent test strip
US4071318A (en) Test composition and device for determining peroxidatively active substances
US4642286A (en) Composition and method for ethanol determination
DK156730B (en) TEST COMPOSITION AND MATERIALS FOR DETERMINING THE EXISTENCE OF GLUCOSE IN A LIQUID SAMPLE AND PROCEDURE FOR SEMIQUANTITATIVE DETERMINATION OF GLUCOSE IN URINE
JPH01197653A (en) Method and reagent for analyzing peracid
US4786596A (en) Method of preparing a test strip for alcohol testing
EP0036543A1 (en) Improved method and device for the semiquantitative determination of glucose in aqueous fluids and method of preparing the device
US4251222A (en) Sensitizers for peroxidative activity tests
CA1144050A (en) Bilirubin-resistant determination of uric acid and cholesterol
JPH0146029B2 (en)
CS226718B2 (en) Composition for removing ascorbic acid from aqueous liquid substances
JP2950592B2 (en) Multilayer analytical tool for fructosamine measurement
WO1987001460A1 (en) Test device for determination of blood in faeces
EP0158964A2 (en) Tester for detecting a substance in a body fluid
CA1134247A (en) Bilirubin-resistant determination of uric acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1986905443

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1986905443

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1986905443

Country of ref document: EP